Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2019-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to determine the effectiveness and safety of early vitamin K1 use in reducing the risk of bleeding and improving prognosis in patients with spontaneous intracerebral hemorrhage. Patients with spontaneous intracerebral hemorrhage (excluding rupture of aneurysm and vascular malformation) will be randomly divided into experimental group and control group. All the patients in the two groups were treated according to the guideline of spontaneous intracerebral hemorrhage. Patients in the experimental group was treated with intravenous injection of vitamin K1 20mg once a day for 2 days after admission, and the patients in control group was treated with normal saline as a control. The hematoma volume, coagulation function, platelet levels and GCS scales of the two groups will be recorded in 0d, 1d, 3d, 7d post bleeding stroke, furthermore, length of ICU stay and total hospitalization, incidence of complications during hospitalization are to be recorded. During the follow-up, mRS score will be recorded at 1m and 6m post bleeding stroke.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage

NCT04820972

Spontaneous Intracerebral Hemorrhage

COMPLETED NA

Minimally Invasive Intracranial Hematoma Aspiration for Spontaneous Intracerebral Hemorrhage

NCT06429553

Spontaneous Cerebral Hemorrhage

RECRUITING NA

The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury

NCT05095857

Subarachnoid Hemorrhage, Aneurysmal Intracerebral Hemorrhage Traumatic Brain Injury

RECRUITING PHASE4

International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage

NCT00928915

Intracranial Hemorrhages

COMPLETED PHASE4

Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study

NCT02639819

Intracerebral Hemorrhage

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Spontaneous intracerebral hemorrhage is a common disease in the department of neurosurgery, which often leads to long-term coma and severe neurological dysfunction. The amount of cerebral hemorrhage is directly related to the prognosis of the patients, and a small number of patients still suffer from the adverse consequences of delayed bleeding after active treatment. Vitamin K1 is a necessary ingredient in the liver to produce clotting factors II, VII, IX, and X, and vitamin K1 supplementation increases clotting function. On the contrary, vitamin K1 increases the risk of thrombosis. In this study, patients with spontaneous intracerebral hemorrhage (excluding rupture of aneurysm and vascular malformation) will be randomly divided into experimental group and control group. All the patients in the two groups were treated according to the guideline of spontaneous intracerebral hemorrhage. Patients in the experimental group was treated with intravenous injection of vitamin K1 20mg once a day for 2 days after admission, and the patients in control group was treated with normal saline as a control. The hematoma volume, coagulation function, platelet levels and GCS scales of the two groups will be recorded in 0d, 1d, 3d, 7d post bleeding stroke, furthermore, length of ICU stay and total hospitalization, incidence of complications during hospitalization are to be recorded. During the follow-up, mRS score will be recorded at 1m and 6m post bleeding stroke. Finally, the effectiveness and safety of early vitamin K1 use in reducing the risk of bleeding and improving prognosis in patients with spontaneous intracerebral hemorrhage will be analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Haemorrhage in Cerebellum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

patient and family members

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

research group

normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。

Group Type EXPERIMENTAL

Vitamin K 1

Intervention Type DRUG

Research group use Vitamin K1

placebo group

normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1

Group Type PLACEBO_COMPARATOR

normal saline

Intervention Type DRUG

Placebo group use normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin K 1

Research group use Vitamin K1

Intervention Type DRUG

normal saline

Placebo group use normal saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spontaneous intracerebral hemorrhage (Non - aneurysmal or arteriovenous malformations which confirmed by cerebral arterial CT enhancement or DSA);
* Age 18-65 years, male or non-pregnant female;
* GCS score at admission (4 to12);
* during the hospitalization, no urokinase and other hemostatic drugs were used except for etamsylate and vitamin K1;
* informed consent signed by the patient's family

Exclusion Criteria

* irregular lobulated hematoma (volume of hematoma can not be calculated accurately), such as intraventricular hemorrhage;
* severe liver disease or impaired liver function;
* pregnant or lactating women;
* history of using anticoagulation or antiplatelet aggregation drug (including Cilostazol, aspirin, dipyridamole, heparin, low molecular weight heparin, hirudin, dabigatran, and warfarin);
* non-accepted informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No